Keryx Biopharmaceuticals, Inc. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 85

Keryx Biopharmaceuticals, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Keryx Biopharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on the Keryx Biopharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Keryx Biopharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Keryx Biopharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Keryx Biopharmaceuticals, Inc. - Brief Keryx Biopharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Keryx Biopharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Keryx Biopharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Keryx Biopharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Keryx Biopharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Keryx Biopharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Keryx Biopharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Keryx Biopharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Keryx Biopharmaceuticals, Inc. and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of Keryx Biopharmaceuticals, Inc.; Keryx Biopharmaceuticals, Inc. - Key Therapeutics; Keryx Biopharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Keryx Biopharmaceuticals, Inc. - News; Keryx Biopharmaceuticals, Inc. - Latest Updates; Keryx Biopharmaceuticals, Inc. - Pipeline; Keryx Biopharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Keryx Biopharmaceuticals, Inc. Snapshot
Keryx Biopharmaceuticals, Inc. Overview
Key Information
Key Facts
Keryx Biopharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Keryx Biopharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Keryx Biopharmaceuticals, Inc. – Pipeline Products Glance
Keryx Biopharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Keryx Biopharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Keryx Biopharmaceuticals, Inc. – Drug Profiles
GPX 100
Product Description
Mechanism of Action
R&D Progress
KRX-0401 + Xeloda
Product Description
Mechanism of Action
R&D Progress
KRX-0601
Product Description
Mechanism of Action
R&D Progress
Perifosine
Product Description
Mechanism of Action
R&D Progress
Perifosine + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Perifosine + Docetaxel + Prednisone
Product Description
Mechanism of Action
R&D Progress
Perifosine + Gleevec
Product Description
Mechanism of Action
R&D Progress
Perifosine + Lenalidomide + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Perifosine + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Perifosine + Sorafenib
Product Description
Mechanism of Action
R&D Progress
Perifosine + Sunitinib Malate
Product Description
Mechanism of Action
R&D Progress
Perifosine + Velcade + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Zerenex
Product Description
Mechanism of Action
R&D Progress
Keryx Biopharmaceuticals, Inc. – Pipeline Analysis
Keryx Biopharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Keryx Biopharmaceuticals, Inc. – Pipeline Products By Target
Keryx Biopharmaceuticals, Inc. – Recent Pipeline Updates
Keryx Biopharmaceuticals, Inc. - Dormant Projects
Keryx Biopharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
KRX-0403
Keryx Biopharmaceuticals, Inc. – Company Statement
Keryx Biopharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Keryx Biopharmaceuticals, Inc., Deals Summary
Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Keryx Biopharmaceuticals Acquires Accumin From AusAm Biotechnologies
Partnerships
AEterna Zentaris Enters Into Development Agreement With Keryx Biopharmaceuticals
Licensing Agreements
Keryx Biopharma Enters Into Licensing Agreement With Japan Tobacco And Torii Pharma
KYOWA HAKKO KOGYO Enters Into Licensing Agreement With Keryx Biopharmaceuticals
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Panion & BF Biotech
Keryx BioPharma Enters Into Licensing Agreement With Krenitsky Pharma
AEterna Zentaris Enters Into Licensing Agreement With Keryx Biopharmaceuticals
Equity Offering
Keryx Biopharmaceuticals Completes Underwritten Public Offering Of $33 Million
Keryx Biopharmaceuticals Completes Registered Direct Offering Of $20 Million
Keryx Biopharmaceuticals Completes Private Placement Of $82.8 Million
Keryx Biopharmaceuticals Completes Public Offering Of $81.2 Million
Keryx Biopharmaceuticals Completes Private Placement Of Shares For $32 Million
Acquisition
Keryx Biopharmaceuticals Acquires ACCESS Oncology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Keryx Biopharmaceuticals, Inc., Key Information
Keryx Biopharmaceuticals, Inc., Key Facts
Keryx Biopharmaceuticals, Inc. – Pipeline by Indication, 2012
Keryx Biopharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Keryx Biopharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Keryx Biopharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Keryx Biopharmaceuticals, Inc. – Phase III, 2012
Keryx Biopharmaceuticals, Inc. – Phase II, 2012
Keryx Biopharmaceuticals, Inc. – Phase I, 2012
Keryx Biopharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012
Keryx Biopharmaceuticals, Inc. - Pipeline By Target, 2012
Keryx Biopharmaceuticals, Inc. – Recent Pipeline Updates, 2012
Keryx Biopharmaceuticals, Inc. - Dormant Developmental Projects,2012
Keryx Biopharmaceuticals, Inc. - Discontinued Pipeline Products, 2012
Keryx Biopharmaceuticals, Inc., Subsidiaries
Keryx Biopharmaceuticals, Inc., Deals Summary
Keryx Biopharmaceuticals Acquires Accumin From AusAm Biotechnologies
AEterna Zentaris Enters Into Development Agreement With Keryx Biopharmaceuticals
Keryx Biopharma Enters Into Licensing Agreement With Japan Tobacco And Torii Pharma
KYOWA HAKKO KOGYO Enters Into Licensing Agreement With Keryx Biopharmaceuticals
Keryx Biopharmaceuticals Enters Into Licensing Agreement With Panion & BF Biotech
Keryx BioPharma Enters Into Licensing Agreement With Krenitsky Pharma
AEterna Zentaris Enters Into Licensing Agreement With Keryx Biopharmaceuticals
Keryx Biopharmaceuticals Completes Underwritten Public Offering Of $33 Million
Keryx Biopharmaceuticals Completes Registered Direct Offering Of $20 Million
Keryx Biopharmaceuticals Completes Private Placement Of $82.8 Million
Keryx Biopharmaceuticals Completes Public Offering Of $81.2 Million
Keryx Biopharmaceuticals Completes Private Placement Of Shares For $32 Million
Keryx Biopharmaceuticals Acquires ACCESS Oncology

List of Figures
Keryx Biopharmaceuticals, Inc. – Pipeline by Indication, 2012
Keryx Biopharmaceuticals, Inc. – Pipeline by Stage of Development, 2012
Keryx Biopharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012
Keryx Biopharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2012
Keryx Biopharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Ixia - Company Analysis
• Amazon - Point of Realization in 2013?
• Dell Inc.
• Tektronix, Inc.